Record-Breaking Price Movement
The stock of Gujarat Kidney & Super Speciality Ltd surged to an intraday high of Rs 171.8, closing at Rs 172.00, which represents the highest price level ever recorded for the company. This peak price is exactly the 52-week high, with the stock currently at the upper limit of its annual trading range, having gained 75.06% from its 52-week low of Rs 98.25. The day’s performance saw a 2.29% increase, outperforming the Sensex which rose by 0.34% on the same day.
Recent Performance and Momentum
Gujarat Kidney & Super Speciality Ltd has demonstrated strong momentum, with the stock gaining for three consecutive days and delivering a cumulative return of 7.6% during this period. Over the past week, the stock has appreciated by 11.76%, significantly outperforming the Sensex which declined by 0.13%. The one-month performance is even more striking, with a 34.48% rise compared to the Sensex’s 2.30% fall. Over three months, the stock has gained 29.76%, well ahead of the Sensex’s 3.35% increase.
Longer-Term Performance Context
Year-to-date, Gujarat Kidney & Super Speciality Ltd has delivered an impressive 67.40% return, contrasting sharply with the Sensex’s decline of 9.84%. While the stock’s one-year, three-year, five-year, and ten-year returns are recorded as zero, this is likely due to data availability or classification, but the recent surge clearly highlights a period of strong upward price movement. The company’s micro-cap status and hospital sector classification place it in a niche segment where such price appreciation is noteworthy.
Technical Indicators and Trend Analysis
The technical outlook for Gujarat Kidney & Super Speciality Ltd is mildly bullish. The stock is trading above all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained upward momentum. Key technical indicators such as MACD and Bollinger Bands are bullish on the weekly timeframe, while the Dow Theory confirms bullish trends on both weekly and monthly scales. The Relative Strength Index (RSI) shows a bearish signal, suggesting some caution in the short term, but overall technical sentiment remains positive.
Support and Resistance Levels
Immediate support is anchored at the 52-week low of Rs 98.25, providing a strong base for the stock. Resistance levels previously noted at Rs 148.67 (20-day moving average) and Rs 132.52 (100-day moving average) have been decisively surpassed. The current all-time high of Rs 172 now serves as a key resistance benchmark, with the stock closing at this level on 03 Sep 2026.
Valuation Metrics Reflect Premium Pricing
The stock’s valuation multiples indicate a premium pricing environment. The price-to-earnings (P/E) ratio stands at 84 times trailing twelve months earnings, while the price-to-book value (P/BV) is 5.29 times. Enterprise value multiples are also elevated, with EV/EBITDA at 48.54 times and EV/EBIT at 58.80 times, reflecting high market expectations relative to earnings and operating cash flows. The EV/Sales ratio is 15.94 times, and EV/Capital Employed is 5.80 times. Dividend metrics are not applicable as the company has no recent dividend payouts.
Quality and Financial Strength
Gujarat Kidney & Super Speciality Ltd’s quality assessment highlights several strengths. The company exhibits excellent growth and capital structure, with a strong return on capital employed (ROCE) averaging 26.45%, indicating efficient use of capital. Management risk is assessed as average, while growth metrics remain excellent. The company maintains low leverage, with an average debt to EBITDA ratio of 0.92 and net debt to equity at zero, underscoring a strong balance sheet. No promoter share pledging is reported, and institutional holdings are modest at 5.44%.
Recent Financial Trends
Short-term financial trends are positive, with the latest six-month period showing a profit after tax (PAT) of ₹10.22 crores, reflecting a growth rate of 66.99%. Net sales for the same period stand at ₹64.87 crores, indicating healthy revenue generation. Profit before tax excluding other income for the latest quarter is ₹6.27 crores, growing at 23.1% compared to the previous four-quarter average. These figures demonstrate solid operational performance contributing to the stock’s upward trajectory.
Trading Volumes and Market Activity
Delivery volumes have shown a marked increase, with a 154.85% rise over the trailing one-month period compared to the previous month. On 02 Sep 2026, delivery volume was 3.68 lakh shares, representing 41.94% of total volume, higher than the five-day average of 36.47%. This heightened trading activity supports the price appreciation and reflects increased market participation in the stock.
Mojo Score and Rating Update
According to MarketsMOJO, Gujarat Kidney & Super Speciality Ltd holds a Mojo Score of 62.0, with a current Mojo Grade of ‘Hold’. This represents a downgrade from a previous ‘Buy’ rating issued on 24 Aug 2026. The rating adjustment reflects a reassessment of the stock’s valuation and risk profile amid its recent price surge. The company is classified as a micro-cap within the hospital sector, which may influence the grading due to liquidity and market size considerations.
Summary of the Stock’s Journey to the Peak
Gujarat Kidney & Super Speciality Ltd’s journey to its all-time high has been characterised by consistent gains over recent months, supported by strong financial results and positive technical signals. The stock’s ability to outperform the broader market and its sector peers, combined with solid quality metrics and a robust balance sheet, has culminated in this milestone. While valuation multiples suggest a premium, the company’s operational performance and growth metrics provide context for the elevated pricing.
Conclusion
The attainment of an all-time high price of Rs 172 by Gujarat Kidney & Super Speciality Ltd on 03 Sep 2026 marks a significant event in the company’s market history. This achievement reflects a combination of strong financial performance, positive technical trends, and sustained investor interest. The stock’s recent gains have outpaced the Sensex and sector benchmarks, underscoring its standout performance within the hospital industry. The current valuation and rating indicate a cautious stance, balancing the company’s strengths with the premium pricing environment.
